Role for newer @entity3405 antibiotics in treatment of XXXX .

@entity1 @entity2892 @entity796 @entity390 @entity3405 @entity4034 @entity9234 @entity794 @entity3524 @entity8307 @entity1398 @entity325 @entity8933 @entity2718 @entity5505
Monotherapy of @entity4034 with the newer broad-spectrum @entity3405 antibiotics has become attractive because of the efficacy, safety, and cost of these antibiotics when compared with conventional combination therapy. @entity2892 / @entity9234 is a recent and promising addition to this antibiotic family. Experience with @entity2892 / @entity9234 and that reported for @entity3524 , @entity5505 , and @entity8933 in the treatment of biopsy-proved @entity4034 was compared, using data from published reports from five centers. Two hundred forty-three @entity1 were evaluable: 34 were treated with @entity2892 / @entity9234 , 84 with @entity3524 , 122 with @entity5505 , and 33 with @entity8933 . @entity794 was isolated by 80 bone cultures and was the most common single species encountered. There were 75 isolates of @entity796 , 113 mixed Enterobacteriaceae species, 115 mixed gram-positive and -negative isolates of miscellaneous species, and 30 anerobic isolates. @entity325 was present in 101 cases (41.6 percent). Failure rates were similarly low in all groups (10 to 30 percent). However, resistance developed during therapy in all groups with @entity796 . Side effects were predictably few, but reversible @entity1398 , @entity8307 due to @entity2718 , and @entity390 required therapy to be discontinued in seven @entity1 . @entity2892 / @entity9234 should prove to be a very effective and relatively safe single agent for treatment of @entity4034 .
